ABSTRACT
Although much has been written concerning the assessment of bioequivalence using systemic absorption, bioavailability assessments of nonsystemically absorbed drug products, or products whose therapeutic site of action may be localized to the site of application, have been minimally addressed in regulatory guidances and elsewhere in the literature.
